Fraunhofer Institute for Toxicology and Experimental Medicine

Personalized Tumor Therapy

Our Services

Expertise

Scientists at the Regensburg site of Fraunhofer ITEM have extensive expertise in the detection, isolation, and analysis of rare cell populations as well as small amounts of nucleic acids.

Our goal is to advance targeted diagnostics for prevention and therapy for patients with systemic cancers and to improve the preclinical development of new pharmaceutical compounds.

For example, we use Multiomics analysis of single cells and innovative preclinical cell models from patient samples acquired from specific projects for the purpose of generating molecular and functional data. In addition, our GDPR-compliant data management and in-house bioinformatics enable tailored data analysis for developing applications and products for our customers.

Method development

Preanalytics & diagnostics
Multiomics & single-cell analysis
Preclinical cell models & pharmaceutical compound testing
Bioinformatics & math. modeling

Preclinical application

Customized assays and analyses for the preclinical testing of pharmaceutical compounds and novel immunotherapies
Biomarker identification
Development/validation of diagnostic tests

Clinical Translation

Clinical drug development and biomarker identification
Design and implementation of clinical studies at our site in Regensburg and throughout Bavaria (BZKF)

Highlight: Platform for Ex-Vivo Drug Response Assays (PEDRA)

We have developed a Platform for Ex-Vivo Drug Response Assays (PEDRA) that mirrors the clinical patient situation in vitro by using disease-specific models generated from clinical samples, recruited individually for each project. PEDRA comprises several ex-vivo assays of variable cellular complexity. In combination with state-of-the-art readouts drug safety and efficacy can be assessed for a broad range of anticancer treatments. Because PEDRA preserves the original cellular composition of the organ of interest, it is ideal for testing novel IO therapies incl. CPI and ADC.

© Fraunhofer ITEM, Tonia Bargmann
PEDRA: Disease-specific, patient-derived models for preclinical testing of anti-cancer therapies

Certification of Our “Personalized Tumor Therapy” Division by TÜV SÜD

The “Personalized Tumor Therapy” division at the Regensburg site of Fraunhofer ITEM has been certified by TÜV Süd according to DIN ISO 9001:2015 and thus complies with national international standards in quality management. This is of benefit both to our R&D services and to our customers:

Long-term quality assurance
Risk minimization
Global comparability
Continuous optimization of work processes
Early detection of potential for improvement
Fulfillment of specific customer requirements
Greater satisfaction of customers and employees

Contact

Contact Press / Media

Priv.-Doz. Dr. Bernhard Michael Polzer

Deputy Division Director Personalized Tumor Therapy & Head of Department of Bioinformatics and Clinical Translation

Send email
bernhard.michael.polzer@item.fraunhofer.de
Follow me on LinkedIn

Contact Press / Media

Dr. Christian Werno

Head of Department of Molecular and Functional Assays

Send email
christian.werno@item.fraunhofer.de